Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Efficacy and Safety of Apixaban in Korean Frail Atrial Fibrillation Patient
- Conditions
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 2500
- Registration Number
- NCT05773222
- Locations
- 🇰🇷
Seoul National university Hostpital, Seoul, Jongno-gu, Korea, Republic of
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20000
- Registration Number
- NCT05757869
- Locations
- 🇺🇸
The Queens Medical Center, Honolulu, Hawaii, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Advocate Heart Institute, Oak Lawn, Illinois, United States
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 6660
- Registration Number
- NCT05735639
- Locations
- 🇬🇧
Imperial College Hospital NHS Foundation Trust, London, United Kingdom
Venous Thromboembolism Prevention in Outpatients With Glioma
- Conditions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- University of Vermont Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT05683808
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14830
- Registration Number
- NCT05643573
- Locations
- 🇨🇳
Hwa Mei Hospital, University of Chinese Academy Sciences, Ningbo, Zhejiang, China
🇨🇳Xuanwu Hospital Capital Medical University, Beijing, China
🇨🇳Beijing Tongren Hospital, Capital Medical University (West), Beijing, China
Pharmacokinetics of Apixaban in Peritoneal Dialysis
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 50
- Registration Number
- NCT05532878
- Locations
- 🇭🇰
Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong
Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Loewenstein Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05484557
- Locations
- 🇮🇱
Loewenstein Rehabilitation Hospital, Ra'anana, Israel
An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 600
- Registration Number
- NCT05471830
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2437
- Registration Number
- NCT05461807
- Locations
- 🇩🇪
Bayer, Wuppertal, Germany
Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77814
- Registration Number
- NCT05438888
- Locations
- 🇯🇵
Pfizer Site, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.